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Abstract
Background: The Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome is present in at least 1 out of 4,500 female live
births and is the second most common cause for primary amenorrhea. It is characterized by vaginal and uterine
aplasia in an XX individual with normal secondary characteristics. It has long been considered a sporadic anomaly,
but familial clustering occurs. Several candidate genes have been studied although no single factor has yet been
identified. Cases of discordant monozygotic twins suggest that the involvement of epigenetic factors is more likely.
Methods: Differences in gene expression and methylation patterns of uterine tissue between eight MRKH patients
and eight controls were identified using whole-genome microarray analyses. Results obtained by expression and
methylation arrays were confirmed by qRT-PCR and pyrosequencing.
Results: We delineated 293 differentially expressed and 194 differentially methylated genes of which nine overlap
in both groups. These nine genes are mainly embryologically relevant for the development of the female genital
tract.
Conclusion: Our study used, for the first time, a combined whole-genome expression and methylation approach
to reveal the etiology of the MRKH syndrome. The findings suggest that either deficient estrogen receptors or the
ectopic expression of certain HOXA genes might lead to abnormal development of the female reproductive tract.
In utero exposure to endocrine disruptors or abnormally high maternal hormone levels might cause ectopic
expression or anterior transformation of HOXA genes. It is, however, also possible that different factors influence the
anti-Mullerian hormone promoter activity during embryological development causing regression of the Müllerian
ducts. Thus, our data stimulate new research directions to decipher the pathogenic basis of MRKH syndrome.
Background
The Mayer-Rokitansky-Küster-Hauser (MRKH) syn-
drome (OMIM 277000) is the second most common
cause of primary amenorrhea and affects at least 1 in
4,500 females. It is characterized by congenital absence
of the uterus and the upper two thirds of the vagina in
women with a normal female karyotype. As the ovaries
are functional, women affected have physiological hor-
mone levels and normal secondary sexual characteristics
[1]. The MRKH syndrome may occur isolated (type I),
or can be associated with renal or skeletal malforma-
tions, and, to a lesser extent, auditory and cardiac
defects (type II) [2]. Although it is generally sporadic,
familial clustering has been described, indicating a
genetic cause [3]. Familial cases have been explained by
autosomal dominant inheritance with incomplete pene-
trance and variable expressivity or by small chromoso-
mal aberrations undetectable in standard karyotypes [4].
However, the lack of families with informative genetic
histories has not allowed the identification of any locus
using standard genetic linkage analysis. Investigations
have therefore used a candidate gene approach based on
association with other genetic diseases or involvement
during embryogenesis [4].
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(MD) development with renal, skeletal, cardiac and
auditory defects suggests that crucial genes of fetal
development and sex differentiation such as HOX, WNT
and those encoding anti-Müllerian hormone (AMH) and
its receptor are potential candidates [5,6]. The WNT
genes control the production of a large family of pro-
teins involved in intercellular signaling during embryo-
genesis. Heterozygous mutations of WNT4 have been
detected in a subgroup of patients, but these patients
also show signs of hyperandrogenism [7-10]. HOX genes
play key roles in body patterning and organogenesis, in
particular during genital tract development and the dif-
ferentiation of the kidneys and skeleton. Thus, expres-
sion or function defects in one or several HOX genes
may account for this syndrome. Furthermore, several
hormones regulate physiological processes in the adult
female reproductive tract by regulating HOX gene
expression. Alterations in HOX gene expression that
persist in the adult are a molecular mechanism by
which endocrine disruptors may affect reproductive
tract development [11,12]. However, structural abnorm-
alities in HOX genes or in hormones regulating HOX
expression have not been identified in women with
MRKH syndrome until today [13-17]. As a third group
of genes, AMH and its receptor have been regarded as
causative factors in MRKH syndrome as AMH initiates
MD regression in the 6th gestational week [18-22].
Mutation analyses of the AMH gene, however, did not
support a link between MRKH syndrome and AMH yet
[18,23]. Finally, mutations in other genes with a broad
spectrum of activity during early development such as
WT1, PAX2 and others have also been excluded in
MRKH patients [4].
From the previous studies one can conclude that the
targeted candidate gene approach has failed to decipher
the causes of MRKH syndrome [2,5,24]. Recently, sev-
eral recurrent copy number variants in patients with iso-
lated and syndromic Müllerian aplasia have been
described, but none of them was consistently found in a
larger group of patients [25].
Cases of discordant monozygotic twins suggest that
the involvement of epigenetic factors is more likely. Sev-
eral studies have identified epigenetic differences, either
for selected genes in monozygotic twins or in the overall
epigenome [26,27].
We provide here the first study using a whole-genome
approach to detect differences at the transcriptome and
methylome level between MRKH patients and healthy
controls. As integrated genomics becomes more and
more important, the synergy between transcriptional
and epigenetic gene regulation may be used to better
understand the etiology of MRKH syndrome.
Methods
Patients
This study was approved by the ethics committee of the
Eberhard-Karls-University of Tuebingen. Between July
2007 and December 2010, we had partly or completely
excised 102 rudimentary uterine structures during
laparoscopic-assisted neovagina in MRKH patients after
informed consent was obtained [28]. As controls, we
included 63 patients who underwent hysterectomy for
benign disease in the same period.
Microarray analysis was performed in eight patients
and eight controls to detect differentially expressed
g e n e sa n ds e v e np a t i e n t sa n ds e v e nc o n t r o l sf r o mt h e
same group to detect differentially methylated CpG
sites. Of these patients, four had MRKH type I and four
had MRKH type II, including three patients with skeletal
malformations, and amongst these, one with Fallot’st e t -
ralogy and one with ureter abnormalities. None of the
patients had MURCS association or other complex
malformations.
Analysis of serum samples at the time of surgery
showed similar distribution between cycle phase one
and two in the patients and control group.
Tissue samples were examined histologically before
RNA and DNA were isolated. All tissue samples in both
groups consisted of more than 80% myometrium.
RNA and DNA isolation
The total RNA from myometrial pieces of rudimentary
u t e r i n et i s s u eo rn o r m a lu t e r u sw a si s o l a t e du s i n gt h e
RNeasy
® Mini Kit (Qiagen, Hilden, Germany). RNA
quality was checked by a Lab-on-a-Chip-System Bioana-
lyzer 2100 (Agilent, Boeblingen, Germany), and the con-
centration was determined using a BioPhotometer
(Eppendorf, Hamburg, Germany). DNA was isolated
using the DNeasy
® purification Kit (Qiagen, Hilden,
Germany) according to protocol and the concentration
was determined using a BioPhotometer (Eppendorf).
Affymetrix microarray analysis
Double-stranded cDNA was synthesized from 100 ng of
total RNA and subsequently linearly amplified and bioti-
nylated using the GeneChip
® WT cDNA Synthesis and
Amplification Kit (Affymetrix, Santa Clara, CA, USA)
according to the manufacturer’s instructions. 15 μgo f
labeled and fragmented cDNA was hybridized to Gene-
Chip
® Human Gene 1.0 ST arrays (Affymetrix). Arrays
were scanned using the GCS3000 Gene Chip scanner
(Affymetrix) and AGCC 3.0 software. Scanned images
were inspected visually to check for hybridization arti-
facts and proper grid alignment and analyzed with
Expression Console 1.0 (Affymetrix) to generate report
files for quality control.
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Relative expression of selected mRNA targets was deter-
mined by quantitative real-time PCR (qRT-PCR). 250-
500 ng of total RNA was reverse transcribed using a
QuantiTect Reverse Transcription Kit (Qiagen) accord-
ing to the manufacturer. cDNA was diluted 1:10 before
PCR amplification or preamplified using the TaqMan
PreAmp Master Mix Kit (Applied Biosystems, Carlsbad,
CA, USA) according to the manufacturer’sp r o t o c o la n d
diluted 1:20 for the subsequent PCR analysis. Primers
were designed with Primer3 or PrimerBlast (http://bio-
tools.umassmed.edu/bioapps/primer3_www.cgi, http://
www.ncbi.nlm.nih.gov/tools/primer-blast/) and synthe-
sized by Metabion (Metabion, Martinsried, Germany).
Table 1 gives a list of PCR targets and primers.
Real-time detection of specific PCR products was per-
formed on a LightCycler480 (Roche, Penzberg, Germany)
with 5 μL of 2x QuantiTect SYBR Green PCR Kit (Qia-
gen). The PCR reaction was initiated by a 10 min hot start
followed by 45 cycles of 95°C for 20 s, 58°C for 40 s, and
72°C for 20 s. Each PCR reaction was performed in three
technical replicates. PCR efficiency was calculated from 4-
or 5-fold serial dilutions of an equal mixture of all cDNAs
using the following equation: E = 10^[-1/slope] [29]. To
calculate the relative expression of each target, the raw Cp
values were imported into qBase [30]. Three suitable refer-
ence genes (PDH, SDHA, PGRMC1 or HISPPD1)w e r e
selected according to their M-values and used for normali-
zation of the qRT-PCR reactions [31,32].
Illumina methylation array analysis
200-500 ng DNA was bisulfite-converted using the EZ
DNA Methylation Kit (Zymo Research, Orange, CA,
USA) according to the manufacturer’s protocol.
Seven patient and seven control probes were evaluated
for genome-wide promoter methylation using the Illu-
mina Infinium HumanMethylation27 BeadArray.
After bisulfite conversion, each sample was whole-gen-
ome amplified (WGA) and enzymatically fragmented.
The bisulfite-converted WGA-DNA samples were puri-
fied and applied to the BeadChips. Allele-specific primer
annealing is followed by single-base extension using
DNP- and Biotin-labeled ddNTPs. DNA methylation
values, described as beta values, are recorded for each
locus in each sample via BeadStudio software [33].
Differential methylation was assessed by subtracting
the mean methylation level (beta value) of the patient
g r o u pf r o mt h em e a nb e t av a l u eo ft h er e f e r e n c eg r o u p
using BeadStudio software.
Pyrosequencing methylation analysis
PCR and sequencing primer were designed by Qiagen
using the PyroMark Assay Design Software 2.0 and are
shown in Table 2. For each gene, we selected the
sequence of the CpG island region which had previously
been identified as differentially methylated in the array
experiments. One to five adjacent CpG sites were ana-
lyzed for each CpG island. Five patient and five control
samples were included in the experiment. 200 ng of iso-
lated DNA was bisulfite-converted using the EZ DNA
Methylation Kit (Zymo). 24 ng of bisulfite-treated DNA
were amplified in reaction mixture containing forward
and reverse primer, 1 U of HotStarTaq DNA Polymer-
ase (Qiagen), 200 μmol each of dNTP/l and nuclease-
free water. The same cycling conditions were used for
all assays: denaturing at 95°C for 15 min; 35 cycles at
95°C for 10 s, at 59, 3°C for 30 s, and at 72°C for 30 s;
an additional elongation step was performed at 72°C for
Table 1 qRT-PCR targets with corresponding Affymetrix probeset ID and primer used for amplification
Target Affymetrix cluster ID Forward primer Reverse primer
HOXA5 8138735 CGCCCAACCCCAGATCTA GGCCGCCTATGTTGTCATG
HOXA9 8138749 GCTTGTGGTTCTCCTCCAGT CCAGGGTCTGGTGTTTTGTA
PGR 7951165 TGGTGTTTGGTCTAGGATGGA GGATCTGCCACATGGTAAGG
ESR1 8122840 GCAGGGAGAGGAGTTTGTGT CAGGACTCGGTGGATATGG
OXTR 8085138 GCACGGTCAAGATGACTTTC GCATGTAGATCCAGGGGTTG
PEG10 8134339 GACCCCATCCTTCCTGTCTT GCTTCACTTCTGTGGGGATG
MFAP5 7960919 TGCTCTCGTCTTGTCTGTAAGG ACAGGGAGGAAGTCGGAAGT
IRS1 8059470 GTTTCCAGAAGCAGCCAGAG GGAAGATATGAGGTCCTAGTTGTGA
IRS2 7972745 CTTCTTGTCCCACCACTTGA CAGTGCTGAGCGTCTTCTTTT
IGF2 7937772 ACACCCTCCAGTTCGTCTGT CGGAAACAGCACTCCTCAA
WISP2 8062864 GCGACCAACTCCACGTCT GTCTCCCCTTCCCGATACA
CDH5 7996264 ACAACGAGGGCATCATCAA AATGACCTGGGCTCTGTTTC
SDHA 8104166 AGAAGCCCTTTGAGGAGCA CGATTACGGGTCTATATTCCAGA
PDHB 8088384 GAGGCTGGCCACAGTTTG GAAATTGAACGCAGGACCTT
PGRMC1 8169617 GGTGTTCGATGTGACCAAAG TGAGGTCAGAAAGGTCATCGT
HISPPD1 8169617 TCCATCATCTGACGTTCCAC TGGTGTTGGGAGGATCTTTG
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Page 3 of 123 min. Gel electrophoresis was carried out on all PCR
products. All PCR reactions included a no-template con-
trol and four standardized methylation controls (0%,
30%, 70%, and 100% methylated DNA). Pyrosequencing
was carried out using the Pyrosequencer PSQ 96 MA
(Biotage AB, Uppsala, Sweden). Results were automati-
cally analyzed using the PSQ 96MA 1.0 software (Allele
Quantification mode).
Pathway analysis
Gene regulation networks were generated using Ingenu-
ity Pathway analysis software (ingenuity
® systems,
http://www.ingenuity.com). The dataset with differen-
tially regulated transcripts and their corresponding
expression and methylation values were uploaded into
the application. The genes were overlaid onto a global
molecular network developed from information in the
Ingenuity Pathways Knowledge Base. Networks of these
focus genes were then algorithmically generated based
on their connectivity. All edges are supported by at least
one reference from the literature, from a textbook, or
from canonical information stored in the Ingenuity
Pathways Knowledge Base. Genes from the microarray
d a t a s e tt h a tm e tt h ef o l dc h a n g ec u t o f fo f1 . 5a n dt h a t
were associated with a relevant pathway in the Ingenuity
Pathways Knowledge Base were included in the analysis.
Statistical methods
With quantitative RT-PCR normalized values were
obtained from qBase. The ratio of means of patients
divided by means of controls was then calculated and
the log2 of this ratio is shown. For the Affymetrix
microarray analysis the means of patients were divided
by the means of controls and the log2 was shown as log
fold change. Measurement errors were calculated using
Gaussian error propagation. As usual it is assumed that
normalized values obtained from qBase are lognormal
distributed and a t-test (i.e. the Welch test assuming
unequal variances) was applied for each gene to investi-
gate the difference between patients and controls in
qRT-PCR. The same was done for expression array data.
A significance level of 5% was chosen. The percentage
of methylated cytosines was obtained from pyrosequen-
cing methylation analysis. The difference means of
patients minus means of controls are shown. The same
was done for the average beta values.
Results
Microarray expression and methylation analysis
To identify changes in the expression level of putative
candidate genes, we performed microarray analysis with
Affymetrix Human Gene 1.0. Analysis using the
ArrayAssist 4.0 software identified 293 transcripts differ-
entially expressed between tissue samples of MRKH
patients and controls. Of these transcripts, 161 were
upregulated and 132 downregulated with a fold change
of at least 1.5 and a p-value of less than 0.05 (Table 3).
Pathway analysis revealed genes relevant in the embry-
ological development of the genital tract, including
HOXA genes and hormone receptors.
The delineation of regional DNA methylation patterns
has important implications for understanding why cer-
tain regions of the genome can be expressed in specific
developmental contexts and how epigenetic changes
might enable aberrant expression patterns and disease
[27]. We therefore decided to compare whole-genome
expression and methylation patterns in uterine rudi-
ments of MRKH patients compared to control uteri. To
achieve this, we performed Illumina HumanMethyla-
tion27 BeadArrays and overlaid both datasets. The ana-
lysis using the BeadStudio software identified 194
Table 2 Pyrosequencing targets with corresponding Illumina probeset ID and primer used for amplification
Target Illumina Target ID Forward primer Reverse primer Sequencing primer
WISP2 cg03562120 GTGTGTGTTTGGGAGTGATTT Bio-CTCATATCCCCTACAAAACCAACTTTAA GTTTGGGAGTGATTTTATAGTTGT
HOXA5 cg02248486 GGAATTATGATTTTTATAATTAT
GTAATTGGTAGTT
Bio-AACCACAAATCAAACACACATATCA AATTATGATTTTTATAATTATGTAA
TTGGTAG
HOXA9 cg27009703 Bio-GTGGTGATGGTGGTGGTATAT ACTTCAACCCCTACAACTTCCAATCCA TCAACCCCTACAACTTCCAATCCA
AAA
WT1 cg25094569 Bio-TGGATGTGATTTTGGGATAGGT CCCATTTTTAAAACCAAACCATTTAACT ATTTTTAAAAAATAAACAACCTTC
TCTATC
GATA4 cg17795240 AAGGATTGGTTTAGGGAGAGTTTGTTTTG Bio-TAAAATTTCACCATATTAACCAAAAACT
CCTAACCTTA
GGTTTAGGGAGAGTTTGTTTTG
Table 3 Differential expression of genes and methylation
of CpG-sites in MRKH patients compared to controls in
numbers
Difference in patients from controls n
Differential expression, total 293
Downregulated 132
Upregulated 161
Differential methylation, total 194
Hypomethylated 116
Hypermethylated 78
Overlap 9
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islands. Of these sites, 78 were hypermethylated and 116
hypomethylated (Table 3).
Nine genes were detected in both datasets (HOXA5,
H O X A 9 ,W I S P 2 ,C D H 5 ,P E G 1 0 ,M F A P 5 ,L R R C 3 2 ,
RALGPS2, SMPD3); these are termed ‘overlap genes’
(Table 4). CpG sites within these genes were either
hypermethylated and the genes underexpressed or hypo-
methylated and overexpressed, except for one gene.
Of the nine overlap genes, six (CDH5, MFAP5, WISP2,
HOXA5, PEG10, HOXA9) were included in the subse-
quent analyses and experiments as they are known to be
relevant to the embryological development of the female
genital tract.
Network and pathway analysis
Ingenuity Pathways analysis software (Ingenuity Sys-
tems) was used to examine the connection between the
differentially methylated CpG sites and differentially
expressed genes. As shown in Figures 1 and 2, differen-
tially expressed genes and differentially methylated sites
can be assigned to basic functions relevant to cell and
tissue development and proliferation, cell-to-cell signal-
ing and interaction, cellular movement, cancer, endo-
crine and reproductive disorders, and others (Figure 1
and 2).
Figure 3 shows a network of differentially regulated
overlap genes and other relevant genes. The network
was created by fusing the expression and methylation
datasets from the microarray experiments. This specific
network was selected because of the known relevance of
the genes included during embryological development
and during functional changes of the female reproduc-
tive tract. Interactions between embryologically relevant
genes, including HOXA genes and hormone receptors,
can be clearly detected. Interacting genes are either dif-
ferentially expressed, carry differentially methylated CpG
sites, or both. The gene regulation network contains 15
differentially regulated genes, seven downregulated
(green icons), two of these also with hypermethylated
CpG sites (dark grey), and seven upregulated (red
icons), three of these also with hypomethylated CpG
sites (light grey). Four genes contained differentially
methylated CpG sites without being differentially
expressed (three hypo- and one hypermethylated). Eight
genes are supplemented in the network to complete the
interactions. Eleven of the transcripts shown were used
for qRT-PCR validation and five for pyrosequencing.
Figure 4 shows the relation between expression and
methylation in overlap genes later selected for valida-
tion. CpG sites in genes were either hypomethylated
with genes overexpressed or hypermethylated with
genes underexpressed, except for CDH5.
Validation of expression differences by qRT-PCR
We chose nine key players in the interaction networks
for independent verification by qRT-PCR. The genes
were selected because of their known relevance during
embryological development. Three suitable reference
genes (PDH, SDHA, PGRMC1 or HISPPD1)w e r e
selected according to their M-values and used for nor-
malization of the qRT-PCR reactions. We were able to
validate all nine genes. The results of the qRT-PCR (Fig-
ure 5) showed 100% validation efficiency in comparison
to the expression data of the microarray experiment,
although statistical significance was not always found.
Validation of methylation differences by pyrosequencing
Five embryologically important genes were chosen for
validation of the methylation array experiments by
Table 4 Overlap genes: names of differentially expressed genes that contain differentially methylated CpG-sites
Probe set ID,
human 1.0
genechip array
Probe set ID,
27human
methylation
Gene title Gene
symbol
Fold change
human 1.0
genechip array
p-
value
Diff methyl
27human
methylation array
p-
value
8138735 cg02248486 homeobox A5 HOXA5 1.9 0.00036 -0.33 0.00015
8138749 cg26521404 homeobox A9 HOXA9 1.5 na -0.23 0.00047
8062864 cg03562120 WNT1-inducible signaling pathway
protein 2
WISP2 -1.7 0.00148 0.14 0.00096
7996264 cg22319147 cadherin 5, type 2, VE-cadherin
(vascular epithelium)
CDH5 -1.6 0.00503 -0.12 0.00598
8134339 cg19107595 paternally expressed 10 PEG10 1.8 0.00290 -0.12 0.01596
7960919 cg15815843 Microfibrillar-associated protein 5 MFAP5 -2.1 0.04635 0.16 0.02451
7950555 cg20899321 Leucine-rich repeat containing 32 LRRC32 -1.6 0.00435 0.12 0.00045
7907657 cg10559803 Ral GEF with PH domain and SH3
binding motif 2
RALGPS2 2.0 0.00385 -0.11 0.00345
8002249 cg17217677 sphingomyelin phosphodiesterase 3,
neutral membrane (neutral
sphingomyelinase II)
SMPD3 1.6 0.00001 -0.10 0.01602
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within one specific CpG island per gene for analysis
(Figure 6). The CpG islands were selected according to
the differential methylation in the preceding array
experiments. The differential methylation status of the
array experiments was confirmed for all five CpG
islands within the WISP2, HOXA5, HOXA9, GATA4
and WT1 genes, thus validation efficiency was again
100% (Figure 7).
Discussion
Although MRKH syndrome is a congenital disorder
most patients are not diagnosed until puberty. Using a
candidate gene approach, the underlying cause has so
Figure 2 Assignment of all genes containing differentially methylated CpG-sites to functional groups.F i s c h e r ’s exact test was used to
test for significance (shown as bars), determining the probability that each biological function assigned to the network is due to chance alone.
Figure 1 Assignment of differentially expressed genes to functional groups. Assignment of all differentially expressed genes to functional
groups. The analysis was done with Ingenuity Pathways analysis software. Fischer’s exact test was used to test for significance (shown as bars),
determining the probability that each biological function assigned to the network is due to chance alone.
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Page 6 of 12Figure 3 Network of differentially expressed genes and genes containing differentially methylated CpG-sites.T h ef o l dc h a n g eo f
regulation in the microarray analysis, (the p-value of the significance analysis) and the percentage of differential methylation are listed below the
symbols. For the purposes of simplification, only selected known gene-to-gene interactions are shown. Continuous arrow lines show direct
interactions between genes and broken arrow lines show indirect interactions.
Figure 4 Relation between expression and methylation in overlap genes. Methylation (left) and expression (right) of overlap genes in
MRKH patients compared to control group. Methylation is shown as difference of average beta of patients minus controls. Expression differences
are shown as log fold change of patients divided by controls. Bars indicate the measurement error.
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Page 7 of 12far not been identified [5]. Recently, a high incidence of
recurrent copy number variants in patients with isolated
and syndromic Müllerian aplasia has been described,
but none of them was consistently found in a larger
group of patients [25]. Cases of discordant monozygotic
twins suggest that the involvement of epigenetic factors
is more likely. The present study was the first to use a
whole-genome approach to identify relevant genes,
including differential expression and methylation. This
allowed us to create a complex network of genes, which
Figure 6 Similar methylation in adjacent CpG sites within CpG islands.D e g r e eo fm e t h y l a t i o nw i t h i nC p Gi s l a n d s :s h o w na r eb o x - a n d -
whisker plots of the percentage of methylated cytosines for patients (white boxes) and contols (grey boxes). The circled CpG sites correspond to
the specific sites detected in the array experiments.
Figure 5 Validation of differential expression by qRT-PCR.E x p r e s s i o no fo v e r l a pg e n e si nM R K H patients compared to control group
measured by array (left) and qRT-PCR (right). Array data are shown as log fold change of patients divided by controls, qRT-PCR data are shown
as log ratio of patients divided by controls. Bars indicate the measurement error and stars indicate a significant difference between patients and
controls (t-test, p-values <0.05).
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MRKH syndrome. Our data indicate that different
potential mechanisms are possible.
Deficiency of hormone receptors
The overexpression of ESR1 and PGR in rudimentary
uterine tissue from MRKH patients could be explained
b yad e f i c i e n c yo ft h e s eh o r m o n er e c e p t o r s .T h el o c a l
overexpression may be the result of a positive feedback
mechanism well known from other hormonal regulatory
loops. Similar hypotheses have been postulated before
but firm scientific evidence has not yet been obtained.
This is the first study with an experimental setting that
supports the hypothesis of locally deficient hormone
receptors in MRKH syndrome.
As early as 1910, Küster explained the MRKH syn-
d r o m eb yr e g r e s s i o no ft h eMüllerian duct (MD) [34].
According to Ludwig, the MRKH syndrome results from
non-fusion of the MD with the Wolffian duct (WD)
[35,36]. Because the embryo is under the influence of
maternal hormones, he suggested that both the non-
fusion of the MD with the WD and rudimentary devel-
opment of the vagina are caused by a deficiency of
gestagen or estrogen receptors [35,36]. Estrogens are
necessary for the embryonic development of the female
reproductive tract. The special role of ESR1 in female
reproductive tract development has been demonstrated
by disrupting the corresponding gene in the mouse,
resulting in hypoplastic uterine and vaginal tissue [37].
Influence of estrogen on AMH and its receptor
One of the first hypotheses for the underlying cause of
MRKH syndrome was an activating mutation of either
the gene for the AMH receptor (AMHR), resulting in
the inappropriate production of AMH, or the receptor
itself. Schmid-Tannwald and Hauser proposed the
regression of the MD due to a temporary secretion of
AMH during the first fetal weeks [38]. Depending upon
the amount secreted, a greater or lesser portion of the
MD regressed. Nevertheless, mutation analyses of the
AMH gene did not support a link between the MRKH
syndrome and AMH at the genome level. Also, AMH
protein levels in plasma and peritoneal fluid from
MRKH patients were equivalent to control individuals
[18,23]. Our study confirmed the data given, as we did
not see any persistent differential expression or methyla-
tion patterns in the AMH or AMHR genes in adolescent
MRKH patients. However, low or baseline AMH levels
in a female adolescent may not necessarily be correlated
with the patient’s early embryonic exposure to AMH
signaling [23].
It has been reported that estrogen regulates AMH
expression [39]. The constant overexpression of ESR1
found in the rudimentary uterine tissue in our patients
or the in utero exposure to abnormally high maternal
levels of E2 could lead to an increasing AMH promoter
activity during embryological development of the female
genital tract causing uterine and vaginal aplasia.
Transcription factors involved in primary sex determi-
nation are also recruited as important regulators of
AMH transcription. A common regulatory factor impor-
tant for transcription of AMH genes is WT-1. WT-1 is
essential for the embryonic development of the kidneys
and gonads. GATA4 appears to play a predominant role
in sex determination and sex differentiation via AMH
gene regulation [40]. In our study CpG sites within
WT1 and GATA4 were both hypomethylated compared
to the control tissue. This could be a sign of stable
Figure 7 Validation of differential methylation by pyrosequencing. Methylation array (left) and pyrosequencing (right) of overlap genes in
MRKH patients compared to control group. Both are shown as difference of patients minus controls. Bars indicate the measurement error.
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Page 9 of 12activation leading, at least during embryological develop-
ment, to activation of the AMH gene and thus partial
regression of the MD.
Influence of endocrine disruptors on the Müllerian duct
and on the expression of HOX genes
Chemical compounds homologous to steroids can act as
agonists or antagonists in fetuses exposed to them [37].
The involvement of ED with estrogen-like functions
would be an explanation for the findings in MRKH syn-
drome, although the analyses of pregnancy histories
available in all our cases so far failed to identify any
clear association with drug use, illness or exposure to
known substances.
Several examples of a negative impact of estrogens on
uterine development are known. Transient exposure of
the neonatal ewe to estrogens during critical periods
specifically perturbs normal development of the uterus
[41]. Estrogen inhibited caudal progression of develop-
ing MD in the turtle. It has been shown to block devel-
opment of the MD when applied before the start of
differentiation, and the length of the MD varied with
the time point treatment was given [42].
Epithelial-mesenchymal differentiation in the murine
MD is regulated by WNT signaling correlated with
expression of HOX genes. Several nuclear hormonal
receptors regulate the expression of multiple HOX
genes. When a HOX gene is mutated, the body segment
where it is normally expressed typically develops charac-
teristics of the segment anterior to it, an effect known
as anterior transformation. In contrast to Drosophila,i n
vertebrates, targeted mutation in a single HOX gene
usually causes only a subtle transformation. This is
because of genetic duplication and functional redun-
dancy of adjacent genes [11]. The hypomethylation of
specific CpG sites and corresponding overexpression of
HOXA9 could be due to either exposure to a substance
similar to diethylstilbestrol (DES) in utero or a deficient
HOXA10 causing anterior transformation.
It is known that HOXA9 is expressed at high levels in
areas destined to become the fallopian tube, HOXA10 is
expressed in the developing uterus, HOXA11 is
expressed in the primordia of the lower uterine segment
and cervix, and that HOXA13 is expressed in the ecto-
cervix and upper vagina. This expression pattern has
been preserved in mice and humans [43]. Microarray
analysis has shown organ-specific changes in gene
expression profiles in the oviduct, uterus, and vagina
after DES exposure. Changes in HOX and WNT expres-
sion might lead to abnormalities of segment-related
positional identity in the upper part of the MD after
DES exposure [43,44]. Sex steroids have been investi-
gated in the regulation of the HOX genes at the 5’end of
the cluster that determine posterior development,
including development of the reproductive tract [45-48].
Both, HOXA10 and HOXA11 expression, is upregulated
by 17ß-estradiol and progesterone. Changes in HOX
gene expression are a potential marker for the effects of
in utero drug use that may become apparent only at late
stages of development [12]. In utero,D E Se x p o s u r e
shifts HOXA9 expression from the oviducts to the
uterus and decreases HOXA10 as well as HOXA11
expression of the uterus causing a ‘T-shaped’ uterus
with a tube-like phenotype [47]. In human uterine and
cervical cell cultures, DES has induced HOXA9 or
HOXA10 gene expression [12].
Continued HOX gene expression in the adult has been
described in the reproductive tract and may be a
mechanism to retain developmental plasticity [49]. Spe-
cifically HOXA10 and 11 a r ee x p r e s s e di nt h ee n d o m e -
trium and their expression varies in a menstrual cycle-
dependent manner. Although no women with mutations
in HOXA10 and HOXA11 have been described, patients
with lower implantation rates have lower HOXA10 and
HOXA11 expression in the secretory phase [43].
In addition to HOXA9, specific CpG sites in HOXA5
were hypomethylated and the gene overexpressed. This
gene has a crucial role in the specification of the cervical
and upper thoracic region of the skeleton. Its correct
expression is important for the proper patterning of the
embryo. It has been shown that ectopic HOXA5 expres-
sion results in abnormal differentiation [50]. In a similar
manner, ectopic HOXA5 expression at the 5’end of the
cluster might prevent normal differentiation of the MD
or even regression. HOXA5 is known as a transcriptional
regulator of multiple target genes, two of which are p53
and the progesterone receptor (PGR). The overexpression
of PGR in patients may be induced directly by the over-
expression of HOXA5 [51].
Finally, neonatal DES exposure is also known to cause
overexpression of IRS-1 and IGF2, both of which are
included in our network [52].
Impact of WNT genes on uterine development
The WNT genes and products form the WNT signaling
pathway which controls developmental processes. Only
the WNT4 gene has been clearly implicated in atypical
MRKH syndrome before [9]. The phenotype of WNT9b
mutants can be rescued by activation of WNT1 in the
WD, identifying the canonical WNT pathway as a deter-
minant signaling process in MD elongation [37]. A
recent study excluded mutations in the coding
sequences of WNT4, WNT5A, WNT7A and WNT9B in
11 MRKH patients [6]. In our study, CpG sites within
the WISP2 (WNT1 inducible signaling pathway protein
2) gene were hypermethylated and the gene underex-
pressed in rudimentary uterine tissue, thus the relevance
is not clear yet. WISP2 (CCN5), a gene that is important
Rall et al. Orphanet Journal of Rare Diseases 2011, 6:32
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Page 10 of 12in smooth muscle cell proliferation and migration, is an
estrogen-induced gene in the uterus [53].
Conclusion
We were able to draw important conclusions from our
study, the first to compare rudimentary uterine tissue
from MRKH patients and uterine tissue from healthy con-
trols. GATA4, WT1 and constant overexpression of ESR1
might increase AMH promoter activity during embryolo-
gical development, resulting in partial regression of the
MD. Involvement of endocrine disruptors (ED) with estro-
gen-like functions might mimic this effect. The deficiency
of hormone receptors may result in their overexpression
and cause both the non-fusion of the MD with the WD
and rudimentary development of the vagina.
The hypomethylation of specific CpG sites and the
corresponding overexpression of HOXA9 may be due to
either exposure to a substance similar to DES in utero
or deficient HOXA10 causing anterior transformation.
Ectopic HOXA5 expression at the 5’end of the cluster
might prevent normal differentiation of the MD.
Using the synergetic approach of transcriptional and
epigenetic regulation, our study has, for the first time,
provided a deeper insight into the etiology of congenital
vaginal and uterine aplasia, and has significantly
advanced the explanation of MRKH syndrome. Further
investigations will show which of our hypotheses is cor-
rect, but it is already clear that hormone receptors and
HOX genes appear to play a major role and should be
in focus of further examinations.
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